文献速递类风湿关节炎

托法替布对类风湿关节炎患者淋巴细胞的短期、中期和长期影响评估

Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2019-04-02

本文为托法替布治疗类风湿关节炎(RA)的事后分析,评估其对淋巴细胞及感染率的短期、中期和长期影响。结果显示托法替布治疗后绝对淋巴细胞计数(ALC)初期较基线升高,约48个月后逐渐降至稳态,CD4+和CD8+ T细胞计数长期下降,停药后变化可逆。ALC<500 cells/mm3的患者严重感染风险增加,仅监测ALC似乎足以评估感染风险。

要点

  • 托法替布治疗后ALC初期升高,约48个月达稳态,CD4+和CD8+ T细胞长期下降。
  • ALC<500 cells/mm3的患者严重感染风险增加。
  • 仅监测ALC似乎足以评估托法替布治疗RA患者的感染风险。

核心结论

  • 托法替布治疗RA患者中,仅监测ALC似乎足以评估感染风险。

研究设计与样本

  • 事后分析,ALC来自III期研究(12-24个月;n=717-958)及I/II/III期/长期扩展研究(≤117个月;All RA人群;n=7,061)。
  • 淋巴细胞亚群计数(LSC)来自II期研究(暴露1.5-6个月;n=236-486)、ORAL Sequel疫苗子研究(约22个月;n=198)及ORAL Sequel淋巴细胞子研究(约50个月;n=55-1,035)。

主要发现

  • 托法替布治疗导致ALC较治疗前基线初期升高,约48个月后逐渐降至稳态。
  • CD4+和CD8+ T细胞计数在长期治疗中下降,ALC和LSC变化在停药后可逆。
  • ALC<500 cells/mm3的患者严重感染风险增加。
  • CD4+ T细胞、CD8+ T细胞、B细胞或自然杀伤细胞计数与严重感染发生率之间无强关联。
  • ALC与CD4+或CD8+ T细胞计数相关性良好(R=0.65-0.86)。

关键数值与推荐

  • ALC<500 cells/mm3与严重感染风险增加相关。
  • ALC与CD4+或CD8+ T细胞计数的相关系数R=0.65-0.86。

临床怎么用

  • 托法替布治疗RA患者中,仅监测ALC可能足以评估感染风险。
  • ALC<500 cells/mm3的患者需关注严重感染风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Altered lymphocyte cell counts and a potential association with increased infection rates have been reported in RA patients treated with JAK inhibitors. This analysis was undertaken to evaluate the short-, mid-, and long-term effects of tofacitinib on lymphocytes and infection rates in patients with RA. METHODS: In this post hoc analysis, absolute lymphocyte counts (ALCs) were obtained from phase III studies (12-24 months; n = 717-958) and phase I/II/III/long-term extension studies of tofacitinib (≤117 months) (All RA population; n = 7,061); lymphocyte subset counts (LSCs) were from phase II studies (1.5-6 months' exposure; n = 236-486), an ORAL Sequel vaccine substudy (~22 months; n = 198), and an ORAL Sequel lymphocyte substudy (~50 months; n = 55-1,035) of tofacitinib. The reversibility of ALC/LSC changes was evaluated. The relationship of ALC and LSC to infections was analyzed in the All RA population. The value of monitoring ALC alone was assessed by examining correlations between ALCs and LSCs. RESULTS: Tofacitinib treatment resulted in an initial increase in ALC versus pretreatment baseline, which gradually declined to steady state by ~48 months. CD4+ and CD8+ T cell counts decreased over long-term treatment, and ALC and LSC changes were reversible upon treatment cessation. Patients with ALCs of <500 cells/mm3 had an increased risk of serious infections. There was no strong association between CD4+ T cell, CD8+ T cell, B cell, or natural killer cell counts and serious infection incidence rates. ALC and CD4+ or CD8+ T cell counts correlated well (R = 0.65-0.86). CONCLUSION: Our findings indicate that monitoring of ALC alone appears to be adequate to assess infection risk in tofacitinib-treated patients with RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. van Vollenhoven R, Lee EB, Strengholt S, et al. Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019. PMID: 30427585. doi:10.1002/art.40780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。